Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivarmacitinib - Arcutis Biotherapeutics/Jiangsu HengRui Medicine

Next Previous
Drug Profile

Ivarmacitinib - Arcutis Biotherapeutics/Jiangsu HengRui Medicine

Alternative Names: ARQ-252; ARQ-255; Ivarmacitinib sulfate; SHR-0302

Latest Information Update: 09 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Arcutis Biotherapeutics; Jiangsu Hengrui Medicine Co.; Reistone Biopharma
  • Class 2 ring heterocyclic compounds; Amides; Amines; Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Cyclopentanes; Heterocyclic bicyclo compounds; Methyl ethers; Pyrimidines; Pyrroles; Pyrrolidines; Skin disorder therapies; Small molecules; Sulfates; Thiadiazoles
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alopecia areata; Ankylosing spondylitis; Atopic dermatitis; Non-radiographic axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis; Vitiligo
  • Phase II Crohn's disease; Peripheral T-cell lymphoma
  • Phase I Graft-versus-host disease
  • Preclinical Eczema

Most Recent Events

  • 18 Dec 2025 Launched for Alopecia areata in China (PO) before December 2025 (Jiangsu HengRui Medicine pipeline, December 2025)
  • 18 Dec 2025 Launched for Non-radiographic axial spondyloarthritis (Treatment-resistant) in China (PO) before December 2025 (Jiangsu HengRui Medicine pipeline, December 2025)
  • 18 Dec 2025 Launched for Ulcerative colitis in China (PO) before December 2025 (Jiangsu HengRui Medicine pipeline, December 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top